Feasibility of Using a Luminescence-Based Method to Determine Serum Bactericidal Activity against .

Development of a vaccine to limit the impact of antibiotic resistant is now a global priority. Serum bactericidal antibody (SBA) is a possible indicator of protective immunity to , but conventional assays measure colony forming units (CFU), which is time-consuming. A luminescent assay that quantifies ATP as a surrogate measure of bacterial viability was tested on strains FA1090, MS11 and P9-17 and compared to CFU-based readouts. There was a linear relationship between CFU and ATP levels for all three strains ( > 0.9). Normal human serum (NHS) is a common source of complement for SBA assays, but needs to be screened for non-specific bactericidal activity. NHS from 10 individuals were used for serum sensitivity assays-sensitivity values were significantly reduced with the ATP method for FA1090 (5/10, < 0.05) and MS11 (10/10, < 0.05), whereas P9-17 data were comparable for all donors. Our results suggest that measuring ATP underestimates serum sensitivity of and that the CFU method is a better approach. However, mouse anti-P9-17 outer membrane vesicles (OMV) SBA titres to P9-17 were comparable with both methods ( = 0.97), suggesting this assay can be used to rapidly screen sera for bactericidal antibodies to gonococci.